TPP1 and neurodegenerative disease: Whilst subject to a number of limitations imposed by the nature of CLN2 disease and administration method of cerliponase alfa, this study has demonstrated an appropriate and effective methodology for eliciting utility values in an ultra-rare, paediatric neurodegenerative disease.